The overall results obtained with the current study postulated that itraconazole was safe and its implication resulted in significant reductions in the serum levels of CA-125 and P-gp which indicate enhanced tumor shrinkage, reduced drug efflux activity, and greater tumor sensitivity to chemotherapy with subsequent improvement in clinical response which was translated by significant improvements in tumor response, overall response, disease control rate, and progression-free survival. The gene discussed is MUC16; the disease is neoplasm.